+ +

•  

   

     Western blot analysis of Histone H3 (tri methyl K27) expression in Hela cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

Histone H3 trimethylated at lysine 27 (H3K27me3) is a post-translational modification associated with transcriptional repression and chromatin compaction. This epigenetic mark is primarily deposited by Polycomb Repressive Complex 2 (PRC2), with EZH2 serving as the catalytic subunit. H3K27me3 plays crucial roles in maintaining cellular identity by silencing lineage-specific genes during development and differentiation. It is particularly important in X-chromosome inactivation, genomic imprinting, and stem cell pluripotency.

Antibodies targeting H3K27me3 have become essential tools for studying epigenetic regulation. They enable detection of this modification through techniques like chromatin immunoprecipitation (ChIP), immunofluorescence, and Western blotting. In cancer research, these antibodies help investigate the aberrant silencing of tumor suppressor genes, as elevated H3K27me3 levels are linked to aggressive malignancies and poor prognosis. Notably, loss of H3K27me3 in certain tumors serves as a diagnostic marker for specific cancers like malignant peripheral nerve sheath tumors.

Recent studies also explore H3K27me3's role in metabolic memory and neurodegenerative diseases. Commercial antibodies are typically validated using knockout cell lines or peptide competition assays to ensure specificity. Researchers must consider potential cross-reactivity with similar histone modifications (e.g., H3K27me2/me1) and optimize experimental conditions for different biological contexts. These reagents continue to advance our understanding of epigenetic mechanisms in health and disease.